Somatostatin analogues in the therapy of neuroendocrine tumors: Indications, contraindications, side-effects
The presence of somatostatin receptors (SSTRs) is crucial in planning the therapy of patients with neuroendocrine tumors. This applies especially to patients in whom surgery has proven unsuccessful or there are contraindications for it. Increased SSTR expression has been observed in many cancers ori...
Main Authors: | Beata Polowczyk, Marcin Kałużny, Marek Bolanowski |
---|---|
Format: | Article |
Language: | English |
Published: |
Index Copernicus International S.A.
2020-07-01
|
Series: | Postępy Higieny i Medycyny Doświadczalnej |
Subjects: | |
Online Access: | http://phmd.pl/gicid/01.3001.0014.3056 |
Similar Items
-
Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms
by: Federico Gatto, et al.
Published: (2019-08-01) -
Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice
by: Kiesewetter, B., et al.
Published: (2022) -
Chromogranin A: As A Tumor Marker for Neuroendocrine Tumors Diagnosis, Follow-up & Its Correlation with Response to Somatostatin Analogues
by: Manwar A. Mohammed AL-Naqqash
Published: (2016-01-01) -
Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
by: Ström T, et al.
Published: (2019-10-01) -
Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future
by: Anna Kathrin Stueven, et al.
Published: (2019-06-01)